Myocardial infarction and arterial thrombosis in identical newborn twins with homozygosity for the PAI-1 4 G/5 G polymorphism by De Lucia, Vittoria et al.
International Journal of Cardiology xx (2008) xxx–xxx
IJCA-11065; No of Pages 4
www.elsevier.com/locate/ijcard
ARTICLE IN PRESSLetter to the Editor
Myocardial infarction and arterial thrombosis in identical newborn twins
with homozygosity for the PAI-1 4 G/5 G polymorphism
Vittoria De Lucia a,⁎, Maria Grazia Andreassi b, Laura Sabatini c, Lamia Ait-Ali a,
Isabella Spadoni a, Sandra Giusti a
a Department of Pediatric Cardiology, G. Pasquinucci Hospital, G. Monasterio Foundation, Italy
b Laboratory of Cardiovascular Genetics, CNR-Institute of Clinical Physiology, Massa, Italy
c Hematology and Coagulation Laboratory, AOU, Siena, Italy
Received 29 January 2008; accepted 3 May 2008Abstract
Myocardial infarction in the perinatal period, in the absence of congenital heart disease or coronary artery lesions, is rare. The most
common etiology described are the thromboembolism and perinatal asphyxia. We report a case of monozygotic twins who developed, after
birth, acute vascular events and both had PAI-1 4G/4G homozygosity.
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Myocardial infarction (MI) in children is rare overall in
patients without congenital structural cardiac disease or
Kawasaki disease. Reports of neonatal arterial thrombosis
are also extremely rare [1–8]. We report a case of
monozygotic twins who shortly after birth both developed
acute vascular events and were found to have a prothrombo-
tic genetic disposition.
2. Case descriptions
A pair of twin males was delivered by cesarean section at
34 weeks of gestation, complicated by an abortion threat at
29 weeks. The mother was a 25 year old gravida 1 and the
parents were of different ethnic groups and unrelated.⁎ Corresponding author. Dipartimento di Cardiologia Pediatrica,Via
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5 min respectively, was immediately intubated and ventilated
due to respiratory distress. During the first hours of life the
newborn developed cardiac failure. Quantitative determina-
tion of cardiac troponin (cTnI), creatine kinase (CK) and
creatine kinase MB (CK-MB) were performed and values
resulted higher than normal range (cTnI 14 ng/ml,
CK 966 IU/L and CK-MB 197 ng/ml; normal range
cTnI 0–0.04 ng/ml, CK 20–170 IU/L andCK-MB 0.5–
3.2 ng/ml). The patient received inotropic therapy and
continuous infusion of heparin (25 U/Kg/h). Cardiac rate
was 170 bpm and blood pressure 49/24 mmHg. Arterial
blood gas measurement showed normal PaO2 and PaCO2
with pH 7.35 and bicarbonate—5.8 mmol/L. Electrocardio-
graphic findings were consistent with myocardial infarction
with sinus tachycardia, Q wave on DI, aVL and chest leads
V4 toV6. An echocardiographic examination showed a
structurally normal heart with severely depressed global
ventricular performance (LVEF 35%), anterior and septal
hypokinesia and lateral and apical akinesia. Significant lab-
oratory values included CK 718 IU/L, CK-MB 36.7 ng/ml
and cTnI 2.89 ng/ml. Complete blood count, basic chemistrybosis in identical newborn twins with homozygosity for the PAI-1 4 G/5 G
Fig. 1. Complete thrombotic occlusion of the right coronary artery.
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underwent coronary angiography. The first injection in the
ascending aorta showed a thrombotic sub-occlusion of the
left anterior descending coronary artery with left circumflex
and right coronary artery patent. A second aortography
(Fig. 1), performed 5 min later, showed a spontaneous
complete thrombotic occlusion of the right coronary artery.
Immediately after this second injection, the infant developed
signs of inferior myocardial lesion, second and third degree
AV block with subsequent cardiac arrest. During cardiopul-
monary resuscitation, intra-aortic infusion of Urokinase was
administered (single bolus of 4100 U/Kg, followed by aFig. 2. MR-Delay enhancement. Ventricle short axis: fibrosis
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myocardial perfusion. Cardiac enzymes were again risen with
CK 1076 IU/L, CK-MB 79.4 ng/ml and cTnI 15.51 ng/ml.
Echocardiogram showed inferior akinesia with worsening of
global left ventricular function. The patient was transferred to
the Intensive Care Unit and treated with inotropic agents,
intravenous nitrates and low molecular weight heparin with
progressive improvement of his cardiac and general condition.
A control aortography performed 20 days later revealed patent
coronary arteries. At this time echocardiogram showed an
improvement of global ventricular function (LVEF 52%). The
patient was discharged 48 days post admission, prescribed take
home drugs were low molecular weight heparin, salicylic acid,
carvedilol and diuretics.
At one year follow-up, low molecular weight heparin
therapy was stopped. The patient was in good clinical
condition with LVEF 50%, on therapy with carvedilol.
At two years follow-up, the infant underwent cardiac
Magnetic Resonance (MR) that showed anterior and lateral
subendocardial necrosis of the left ventricle (Fig. 2).
Twin B, a 2540 g male infant, APGAR scores 4 and 10 at
1 and 5 min, developed acute left external iliac and common
femoral artery thrombosis at birth and underwent unsuccess-
ful thrombolysis and catheter embolectomy. He was
discharged on low molecular weight heparin therapy and
treated with this therapy for one year. At one year follow-up,
he had residual occlusion of his left common femoral artery.
At two years follow-up, the patient underwent MR
angiography of the lower limbs that evidenced proximal
external iliac artery occlusion and recanalization of super-
ficial femoral artery through collateral vessels (Fig. 3).of the anterior basal septum and anterior–lateral wall.
bosis in identical newborn twins with homozygosity for the PAI-1 4 G/5 G
Fig. 3. MR angiography of the lower limbs. Proximal external iliac artery
occlusion and recanalization of superficial femoral artery through collateral
vessels.
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comprehensive thrombophilia profile revealed normal results
for antithrombin, protein C, protein S, lupus anticoagulants,
homocysteine, factor V Leiden mutation, prothrombin
20210→A polymorphism, methylenetetrahydrofolate reduc-
tase (MHTHFR)677C→polymorphism.
Both twins were found to be homozygous (4G/4G) for the
deleted allele of the plasminogen activator inibitor-1 (PAI-1)
gene.
3. Comments
Few studies have reported neonatal myocardial infarction
or ischemia that can be a possible cause of early neonatal
death [1–8]. The most common etiology described are the
thromboembolism and perinatal asphyxia. It was assumed
that a deficiency of natural anticoagulant factors could be a
cause of perinatal myocardial infarction [9]. This case report
describes the development of acute vascular events after
birth in identical twins who both had PAI-1 4G/4G
homozygosity, that could be the most plausible risk factor
for the arterial thrombotic events.
The gene for PAI-1 has an insertion/deletion polymorph-
ism at position −675 in the promoter region, the 4G/5G
polymorphism, which is related to differences in transcrip-Please cite this article as: De Lucia V, et al, Myocardial infarction and arterial throm
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demonstrated that the 4G allele had higher activity than the
5G allele resulting in increased mRNA transcription in
response to cytokine stimulation compared to the 5G allele,
while there is little or no difference under basal conditions
[10].
Indeed, patients who are homozygous for the 4G allele
have higher plasma PAI-1 antigen levels or activity levels
than patients who are either heterozygous or homozygous for
the 5G-allele, and there is considerable evidence for the
relevance of increased PAI-1 activity in thrombotic disorder
[10–13].
Importantly, neonates and infants with underlying cardiac
disease who are homozygous for the 4G/4G variant of the
PAI-1 promotor polymorphism are at high risk of developing
early thromboembolism during cardiac catheterisation or
insertion of central venous lines for major surgery [14].
Recently, intreventricular hemorrhage associated with sinus
venous thrombosis has been reported in a full-term neonate
with PAI-1 4G/4G genotype [15]. In addition, Baumeister
et al. described deep cerebral venous infarction in a preterm
infant homozygous for PAI-1 4G/4G promoter polymorphism
[16]. On the other hand, PAI-1 expression is dramatically
induced by stress or mild hypoxia. As even an uncomplicated
partum involves mild hypoxia, it may further increase PAI-1
concentrations in babies whose genetic background already
endows them with high PAI-1 plasma concentrations [15]. In
conclusion, our findings suggest that PAI-1 4G/4G genotype
may be a genetic risk factor for perinatal thrombosis.
Further attention and larger prospective studies are required
to establish the relevance of PAI-1 promoter 4G/5G poly-
morphism in the pathogenesis of neonatal myocardial
infarction and any other perinatal thrombotic complications,
especially during cardiac catheterisation.
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